

# Tiago R Marques

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7469448/publications.pdf>

Version: 2024-02-01

118  
papers

8,086  
citations

71102

41  
h-index

53230

85  
g-index

123  
all docs

123  
docs citations

123  
times ranked

10337  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs. Human Brain Mapping, 2022, 43, 300-328.	3.6	30
2	Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study. Psychopharmacology, 2022, 239, 3439-3445.	3.1	8
3	Dynamic and Static Cognitive Deficits in Schizophrenia and Bipolar Disorder After the First Episode. Schizophrenia Bulletin, 2022, 48, 590-598.	4.3	12
4	Genetic variants associated with longitudinal changes in brain structure across the lifespan. Nature Neuroscience, 2022, 25, 421-432.	14.8	75
5	Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. British Journal of Psychiatry, 2022, 221, 740-747.	2.8	6
6	The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study. Molecular Psychiatry, 2021, 26, 4464-4474.	7.9	10
7	GABA-A receptor differences in schizophrenia: a positron emission tomography study using [ <sup>11</sup> C]Ro154513. Molecular Psychiatry, 2021, 26, 2616-2625.	7.9	53
8	Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 677-687.	3.2	11
9	The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis. Molecular Psychiatry, 2021, 26, 1310-1320.	7.9	47
10	Neuroanatomical abnormalities in first-episode psychosis across independent samples: a multi-centre mega-analysis. Psychological Medicine, 2021, 51, 340-350.	4.5	23
11	Parametric Mapping for TSPO PET Imaging with Spectral Analysis Impulsive Response Function. Molecular Imaging and Biology, 2021, 23, 560-571.	2.6	4
12	1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans. Translational Psychiatry, 2021, 11, 182.	4.8	24
13	Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [ <sup>11</sup> C]-PBR28 blocking study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3530-3539.	6.4	4
14	Structural Covariance of Cortical Gyrfication at Illness Onset in Treatment Resistance: A Longitudinal Study of First-Episode Psychoses. Schizophrenia Bulletin, 2021, 47, 1729-1739.	4.3	16
15	Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper. Drug Safety, 2021, 44, 825-834.	3.2	5
16	Antipsychotics, versatility in action. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	1
17	The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. Translational Psychiatry, 2021, 11, 393.	4.8	27
18	Acute acetate administration increases endogenous opioid levels in the human brain: A [ <sup>11</sup> C]carfentanil molecular imaging study. Journal of Psychopharmacology, 2021, 35, 606-610.	4.0	3

#	ARTICLE	IF	CITATIONS
19	Mental health risk factors during the first wave of the COVID-19 pandemic. <i>BJPsych Open</i> , 2021, 7, e195.	0.7	4
20	Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia. <i>Molecular Psychiatry</i> , 2020, 25, 584-602.	7.9	49
21	Using Machine Learning and Structural Neuroimaging to Detect First Episode Psychosis: Reconsidering the Evidence. <i>Schizophrenia Bulletin</i> , 2020, 46, 17-26.	4.3	76
22	An overlapping pattern of cerebral cortical thinning is associated with both positive symptoms and aggression in schizophrenia via the ENIGMA consortium. <i>Psychological Medicine</i> , 2020, 50, 2034-2045.	4.5	18
23	Schizophrenia—An Overview. <i>JAMA Psychiatry</i> , 2020, 77, 201.	11.0	569
24	Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region With Cortical and Subcortical Morphology and Cognition. <i>JAMA Psychiatry</i> , 2020, 77, 420.	11.0	54
25	Treatment of First-Episode Schizophrenia in a Young Woman. <i>JAMA Psychiatry</i> , 2020, 77, 211.	11.0	1
26	T45. THE EFFICACY AND HETEROGENEITY OF ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA: A META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2020, 46, S248-S249.	4.3	1
27	S153. IMPAIRED THETA PHASE-COULPING BETWEEN HIPPOCAMPUS AND MEDIAL PREFRONTAL CORTEX IN SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020, 46, S94-S94.	4.3	0
28	S186. THE EFFECTS OF CHILDHOOD TRAUMA ON HIPPOCAMPAL VOLUME IN FIRST EPISODE PSYCHOSIS: DOES CORTISOL PLAY A ROLE?. <i>Schizophrenia Bulletin</i> , 2020, 46, S109-S109.	4.3	0
29	O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS. <i>Schizophrenia Bulletin</i> , 2020, 46, S28-S28.	4.3	0
30	Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis. <i>NPJ Schizophrenia</i> , 2020, 6, 21.	3.6	23
31	Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An in vivo PET Study With Neuropathological Comparison. <i>Frontiers in Neurology</i> , 2020, 11, 541377.	2.4	9
32	O5.5. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: MULTI-MODAL PET AND FMRI FINDINGS. <i>Schizophrenia Bulletin</i> , 2020, 46, S12-S13.	4.3	0
33	Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. <i>Nature Communications</i> , 2020, 11, 246.	12.8	148
34	Impaired theta phase coupling underlies frontotemporal dysconnectivity in schizophrenia. <i>Brain</i> , 2020, 143, 1261-1277.	7.6	38
35	Cortisol awakening response is decreased in patients with first-episode psychosis and increased in healthy controls with a history of severe childhood abuse. <i>Schizophrenia Research</i> , 2019, 205, 38-44.	2.0	17
36	Translation and cross-cultural adaptation of the Arizona Sexual Scale (ASEX) into Portuguese. <i>Trends in Psychiatry and Psychotherapy</i> , 2019, 41, 247-253.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Commentary: A Position Statement on Sexual Orientation Conversion Therapies by Members of the Board of Directors of the Portuguese Society of Clinical Sexology (SPSC). <i>International Journal of Sexual Health</i> , 2019, 31, 231-232.	2.3	1
38	Cognitive Change in Schizophrenia and Other Psychoses in the Decade Following the First Episode. <i>American Journal of Psychiatry</i> , 2019, 176, 811-819.	7.2	123
39	In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis. <i>JAMA Psychiatry</i> , 2019, 76, 1074.	11.0	50
40	O7.6. GABAA RECEPTOR AVAILABILITY IN PATIENTS WITH SCHIZOPHRENIA: A PET STUDY USING [11C]-RO15. <i>Schizophrenia Bulletin</i> , 2019, 45, S181-S182.	4.3	0
41	Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies. <i>Journal of Neural Transmission</i> , 2019, 126, 1637-1651.	2.8	84
42	Reduced mu opioid receptor availability in schizophrenia revealed with [11C]-carfentanil positron emission tomographic imaging. <i>Nature Communications</i> , 2019, 10, 4493.	12.8	30
43	The association of psychosocial risk factors for mental health with a brain marker altered by inflammation: A translocator protein (TSPO) PET imaging study. <i>Brain, Behavior, and Immunity</i> , 2019, 80, 742-750.	4.1	6
44	32.4 A NOVEL TREATMENT FOR COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA BY ENHANCING THE ACTIVITY OF PARVALBUMIN INTERNEURONS. <i>Schizophrenia Bulletin</i> , 2019, 45, S142-S143.	4.3	2
45	F80. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS: PET AND MR IMAGING FINDINGS IN FIRST EPISODE AND CHRONIC SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2019, 45, S284-S284.	4.3	0
46	Metabolic-inflammatory status as predictor of clinical outcome at 1-year follow-up in patients with first episode psychosis. <i>Psychoneuroendocrinology</i> , 2019, 99, 145-153.	2.7	36
47	Jumping to conclusions at first onset of psychosis predicts longer admissions, more compulsory admissions and police involvement over the next 4 years: the GAP study. <i>Psychological Medicine</i> , 2019, 49, 2256-2266.	4.5	14
48	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. <i>Biological Psychiatry</i> , 2019, 85, e35-e39.	1.3	5
49	Neuroinflammation in schizophrenia: meta-analysis of <i>in vivo</i> microglial imaging studies. <i>Psychological Medicine</i> , 2019, 49, 2186-2196.	4.5	151
50	The National Student Survey: validation in Portuguese medical students. <i>Assessment and Evaluation in Higher Education</i> , 2019, 44, 66-79.	5.6	2
51	Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures. <i>Molecular Psychiatry</i> , 2019, 24, 549-561.	7.9	179
52	F229. Cannabinoid 1 Receptor and Memory Function in First Episode Psychosis: A Multi-Modal PET-fMRI Study. <i>Biological Psychiatry</i> , 2018, 83, S327-S328.	1.3	1
53	Kinetic modelling of [ <sup>11</sup> C]PBR28 for 18 kDa translocator protein PET data: A validation study of vascular modelling in the brain using XBD173 and tissue analysis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1227-1242.	4.3	51
54	Utilising symptom dimensions with diagnostic categories improves prediction of time to first remission in first-episode psychosis. <i>Schizophrenia Research</i> , 2018, 193, 391-398.	2.0	7

#	ARTICLE	IF	CITATIONS
55	Antipsychotic plasma levels in the assessment of poor treatment response in Schizophrenia. Acta Psychiatrica Scandinavica, 2018, 137, 39-46.	4.5	76
56	F68. PREMORBID IQ, EDUCATIONAL LEVEL AND JUMPING TO CONCLUSIONS AS PREDICTORS OF CLINICAL OUTCOME AT FIRST ONSET OF PSYCHOSIS OVER THE NEXT 4 YEARS: THE GAP STUDY. Schizophrenia Bulletin, 2018, 44, S246-S246.	4.3	0
57	O6.7. COMMON NEUROANATOMICAL ABNORMALITIES IN FIRST EPISODE PSYCHOSIS ACROSS SEVERAL INDEPENDENT SAMPLES. Schizophrenia Bulletin, 2018, 44, S92-S92.	4.3	0
58	F180. CANNABINOID 1 RECEPTOR AVAILABILITY & MEMORY FUNCTION IN FIRST EPISODE PSYCHOSIS: A MULTI-MODAL PET-FMRI STUDY. Schizophrenia Bulletin, 2018, 44, S291-S291.	4.3	2
59	O2.4. THE MISSING PIECE IN THE PUZZLE: COGNITIVE DECLINE IN SCHIZOPHRENIA AND BIPOLAR PATIENTS AFTER THE FIRST EPISODE. Schizophrenia Bulletin, 2018, 44, S77-S77.	4.3	0
60	Cortical thickness correlates of minor neurological signs in patients with first episode psychosis. Schizophrenia Research, 2018, 200, 104-111.	2.0	13
61	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, 2018, 84, 644-654.	1.3	627
62	O8.7. COGNITIVE SUBTYPES IN FIRST-EPISODE PSYCHOSIS AND ASSOCIATION TO TREATMENT RESPONSE. Schizophrenia Bulletin, 2018, 44, S98-S99.	4.3	0
63	The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project. Schizophrenia Research, 2018, 195, 306-317.	2.0	17
64	Sexual dysfunction and central obesity in patients with first episode psychosis. European Psychiatry, 2017, 42, 1-7.	0.2	8
65	The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Molecular Psychiatry, 2017, 22, 666-679.	7.9	347
66	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry, 2017, 174, 216-229.	7.2	685
67	Connectomic correlates of response to treatment in first-episode psychosis. Brain, 2017, 140, 487-496.	7.6	47
68	Effects of aripiprazole and haloperidol on neural activation during a simple motor task in healthy individuals: A functional MRI study. Human Brain Mapping, 2017, 38, 1833-1845.	3.6	1
69	An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis. Biological Psychiatry, 2017, 81, 470-477.	1.3	176
70	Clinical utility of magnetic resonance imaging in first-episode psychosis. British Journal of Psychiatry, 2017, 211, 231-237.	2.8	30
71	Authors' reply. British Journal of Psychiatry, 2017, 211, 250-250.	2.8	0
72	Translation and cross-cultural adaptation of the Sexual Function Questionnaire (SFQ) into Brazilian Portuguese. Trends in Psychiatry and Psychotherapy, 2017, 39, 110-115.	0.8	6

#	ARTICLE	IF	CITATIONS
73	117.4 Pet Imaging of Neuroinflammation in Schizophrenia. Schizophrenia Bulletin, 2017, 43, S64-S65.	4.3	4
74	Globally Efficient Brain Organization and Treatment Response in Psychosis: A Connectomic Study of Gyrfication. Schizophrenia Bulletin, 2016, 42, 1446-1456.	4.3	47
75	Effect of high-potency cannabis on corpus callosum microstructure. Psychological Medicine, 2016, 46, 841-854.	4.5	47
76	Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry, the, 2016, 3, 1115-1128.	7.4	59
77	Effects of antipsychotics on cortisol, interleukin-6 and hippocampal perfusion in healthy volunteers. Schizophrenia Research, 2016, 174, 99-105.	2.0	34
78	Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. American Journal of Human Genetics, 2016, 98, 735-743.	6.2	65
79	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. Journal of the Neurological Sciences, 2016, 368, 243-248.	0.6	37
80	Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychological Medicine, 2016, 46, 3231-3240.	4.5	202
81	Effects of aripiprazole and haloperidol on neural activation during the n-back in healthy individuals: A functional MRI study. Schizophrenia Research, 2016, 173, 174-181.	2.0	20
82	Dopamine, Striatum, Antipsychotics, and Questions About Weight Gain. JAMA Psychiatry, 2016, 73, 107.	11.0	12
83	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [ <sup>11</sup> C]IMA107. American Journal of Psychiatry, 2016, 173, 714-721.	7.2	33
84	Satisfaç�o com a Especialidade entre os Internos da Forma�o Espec�fica em Portugal. Acta Medica Portuguesa, 2015, 28, 209-221.	0.4	9
85	Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. Journal of Psychopharmacology, 2015, 29, 892-897.	4.0	51
86	Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. Brain, 2015, 138, 3016-3029.	7.6	90
87	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. Brain, 2015, 138, 3003-3015.	7.6	100
88	Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry, the, 2015, 2, 233-238.	7.4	429
89	Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis. Schizophrenia Bulletin, 2015, 41, 1162-1170.	4.3	223
90	Association between the COMT gene and neurological abnormalities and poorer executive function in psychosis. Psychiatry Research, 2015, 230, 742-743.	3.3	2

#	ARTICLE	IF	CITATIONS
91	A Neuroanatomical Signature for Schizophrenia Across Different Ethnic Groups. <i>Schizophrenia Bulletin</i> , 2015, 41, 1266-1275.	4.3	26
92	White matter integrity as a predictor of response to treatment in first episode psychosis. <i>Brain</i> , 2014, 137, 172-182.	7.6	130
93	The practical management of refractory schizophrenia - the Maudsley Treatment REview and Assessment Team service approach. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 427-438.	4.5	38
94	Role of Environmental Confounding in the Association between FKBP5 and First-Episode Psychosis. <i>Frontiers in Psychiatry</i> , 2014, 5, 84.	2.6	17
95	How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses. <i>European Neuropsychopharmacology</i> , 2014, 24, 1279-1288.	0.7	13
96	Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users. <i>Schizophrenia Bulletin</i> , 2014, 40, 1509-1517.	4.3	364
97	Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. <i>Journal of Nuclear Medicine</i> , 2014, 55, 595-601.	5.0	50
98	Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. <i>Human Brain Mapping</i> , 2013, 34, 272-282.	3.6	97
99	The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. <i>BMC Psychiatry</i> , 2013, 13, 320.	2.6	21
100	“œl am sane but he is mad” Insight and illness attributions to self and others in psychosis. <i>Psychiatry Research</i> , 2013, 207, 173-178.	3.3	10
101	Social Disadvantage: Cause or Consequence of Impending Psychosis?. <i>Schizophrenia Bulletin</i> , 2013, 39, 1288-1295.	4.3	114
102	Cortical Folding Defects as Markers of Poor Treatment Response in First-Episode Psychosis. <i>JAMA Psychiatry</i> , 2013, 70, 1031.	11.0	104
103	Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients. <i>Psychological Medicine</i> , 2012, 42, 1893-1901.	4.5	97
104	Sexual dysfunction in people with prodromal or first-episode psychosis. <i>British Journal of Psychiatry</i> , 2012, 201, 131-136.	2.8	46
105	Confirmation that the AKT1 (rs2494732) Genotype Influences the Risk of Psychosis in Cannabis Users. <i>Biological Psychiatry</i> , 2012, 72, 811-816.	1.3	212
106	The neuro/PsyGRID calibration experiment. <i>Human Brain Mapping</i> , 2012, 33, 373-386.	3.6	30
107	Assessment of the impact of the scanner-related factors on brain morphometry analysis with Brainvisa. <i>BMC Medical Imaging</i> , 2011, 11, 23.	2.7	17
108	The different trajectories of antipsychotic response: antipsychotics versus placebo. <i>Psychological Medicine</i> , 2011, 41, 1481-1488.	4.5	33

#	ARTICLE	IF	CITATIONS
109	Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis. <i>Psychological Medicine</i> , 2011, 41, 463-476.	4.5	102
110	Power calculations for multicenter imaging studies controlled by the false discovery rate. <i>Human Brain Mapping</i> , 2010, 31, 1183-1195.	3.6	43
111	THE EFFECTS OF HALOPERIDOL AND ARIPIPRAZOLE ON RESTING STATE BRAIN PERFUSION IN HEALTHY VOLUNTEERS. <i>Schizophrenia Research</i> , 2010, 117, 238-239.	2.0	0
112	DOES STRESS CONTRIBUTE TO INFLAMMATORY AND METABOLIC ABNORMALITIES IN FIRST EPISODE PSYCHOSIS?. <i>Schizophrenia Research</i> , 2010, 117, 369-370.	2.0	0
113	WHITE MATTER TRACTS AS PREDICTORS OF TREATMENT OUTCOME. <i>Schizophrenia Research</i> , 2010, 117, 459.	2.0	0
114	Obsessive-compulsive disorder as a visual processing impairment. <i>Medical Hypotheses</i> , 2010, 74, 107-109.	1.5	29
115	Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment. <i>Schizophrenia Research</i> , 2010, 116, 234-242.	2.0	253
116	Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. <i>Schizophrenia Research</i> , 2010, 119, 75-78.	2.0	112
117	High-potency cannabis and the risk of psychosis. <i>British Journal of Psychiatry</i> , 2009, 195, 488-491.	2.8	465
118	Brain Blood Flow SPET Imaging in Heroin Abusers. <i>Annals of the New York Academy of Sciences</i> , 2006, 1074, 466-477.	3.8	50